Re:Re:clc agreement and team memebers
According to the CLC agreement project these are the areas we need to look at so I have
assigned the members.
State the objective of the presentation. One slide , Cynthia
State the Healthy People 2020 focus area your group has selected and the rationale for
selection of the specific focus area. one slide, Cynthia
Explain how the focus area relates to the individual, family and community and all age
groups throughout the life span. Elsie , five slides,
Identify ways to enhance or optimize health in the selected focus area using
evidence-based research. A minimum of three peer- reviewed articles must be utilized.
Cora 5 slides
Address the health disparity among different segments of the population for the selected
focus area. Althea 2 slides
Provide a brief description of at least two community resources and at least two website
resources for professionals and clients. Althea 3 slides
Provide a brief profile of at least one health-related organization for the selected focus
area Cynthia 2 slides
THIS IS A GROUP PROJECT- our subject area is HEART
My assignment is: Identify ways to enhance or optimize health in the selected focus
area(heart) using evidence-based research. A minimum of three peer-reviewed articles
must be utilized. (5 slides).
Introduction
Basically, this should involve;
Prevention
Detecting and treating risk factors early
(obesity, overweight, physical inactivity, poor
diet, diabetes, cigarette smoking, high
cholesterol, and high blood pressure)
Early detection and treatment of strokes and
heart disease (Stampfer et al., 2000).
Preventing recurrences of cardiovascular
events
Optimizing Cholesterol Management
to Minimize Cardiovascular Disease
Burden
Hypercholestrolemia screening – cost-effective
preventive strategy.
Cholesterol screening- HDL-C, LDL-C, total
cholesterol, very low-density lipoprotein cholesterol,
and triglycerides.
Manage hypercholesterolemia if detected- prevent heart
disease risk.
Primary prevention- reducing CVD burden- modifiable
risk factors
Secondary prevention- slowing progress of a detected
disease condition (Stampfer et al., 2000).
Statins- very effective in management and prevention.
Primary Prevention- Lifestyle and
Diet
Adherence to lifestyle- exercise, diet, and abstaining
smoking- low risk (Vogenberg & Fendrick, 2010).
Much effort focuses on ;
a. Pharmacologic management- blood lipid levels and
hypertension
b. Improved therapy- congestive heart failure and acute
myocardial infarction (Journal of the American College of
cardiology, 2007).
The measures are costly , medical intervention, and side
effects.
Combining primary prevention measures is very effective.
Risk Assessment
Need to recognize CVD spectrum- optimal risk, lower risk,
intermediate risk, and high risk.
Framingham universal risk score- assists guide lipid therapy
(Journal of the American College of cardiology, 2007).
Preventive interventions can be guided by novel screening
technologies and new CVD risk factors.
Unique opportunities for identifying risks should be used-
pregnancy.
Preeclampsia or eclampsia are early CVD indicator- cerebrovascular
disease and hypertension.
Maternal placental syndromes (Vogenberg & Fendrick, 2010).
Traditional cardiovascular risks– diabetes mellitus, prepregnancy
hypertension, dyslipidemia, obesity, and metabolic syndrome.
Vital Interventions
All women are vulnerable to CVD-
significance of heart-healthy lifestyle.
Need to assess the family history.
Aspirin therapy- stroke prevention.
Algorithm- evaluating CVD risk and
prioritizing preventive interventions.
The risks and barriers should be
communicated.
The guidelines should be disseminated and
implemented among diverse populations.
References
Journal of the American College of cardiology. (2007).
Evidence-Based Guidelines for Cardiovascular Disease
Prevention in Women: 2007 Update.
Stampfer, M. J., Hu, F. B., Manson, J. E., Rimm, E. B.,
& Willett, W. C. (2000). Primary prevention of coronary
heart disease in women through diet and lifestyle. The
New England Journal of Medicine, 343(1), 16- 22.
Vogenberg, F. R., & Fendrick, A. M. (2010).
Cardiovascular risk reduction in the workforce:
optimizing cholesterol management to reduce the burden
of cardiovascular disease. Am J Pharm Benefits, 2(4):
255- 261.